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ABSTRACT 
Objective: Glioblastoma (GBM) is the most common adult primary brain tumour. Human 
cytomegalovirus (HCMV) has been studied for the past decade and conflicting results have 
been reported with no conclusive role has yet been established. Human papillomavirus (HPV) 
is involved in the pathogenesis of many cancers and has high prevalence in cervical and oral 
cancer patients of Pakistan. The objective of our study was to identify the prevalence of 
HCMV and HPV in Pakistani primary GBM patients.  
Methods: 112 primary GBM biopsies were analyzed. HCMV and HPV infection was 
investigated using nested and conventional PCR respectively. Positive HPV samples were 
further confirmed through sequencing. HPV status was correlated with histology and 
expression of other frequently mutated GBM molecular markers. 
Results: Our data had 68% males and 32% females. HCMV was detected in only 1 patient 
while HPV infection was present in 28% of patients with no cases of HPV and HCMV co-
infection. We report for the first time that a majority of HPV positive GBM patients 
harboured types 16 and 18 both. Among them, 16% were HPV-type16 and 20% were HPV-
type 18. HPV infected patients had longer survival times but this was not statistically 
significant. Most commonly overexpressed molecular marker in HPV positive patients was 
COX2, and no histological changes were seen in HPV positive GBM cases. 
Conclusions: The presence of a single HCMV positive is intriguing. Additionally, we 
discovered a substantially high 28% prevalence of HPV in GBM patients. The role of viruses 
in the gliomagenesis warrants further investigation. 
 
 
 
 
Ali. 3 
 
 
 
INTRODUCTION 
Glioblastoma multiforme (GBM), presenting as a common malignant primary brain tumour 
(WHO grade IV astrocytoma), is the deadliest brain tumour with a poor prognosis and an 
almost unavoidable tendency of relapse within a short period of time. The average patient 
survival rate is 14.6 months even after a rigorous multimodal treatment consisting of surgery, 
chemotherapy and radiotherapy. The 5-year survival rate with maximum available 
multimodal therapy is a mere 5.5% 1,2. 
GBM has an incidence of 3.2 per 100,000 adults in the US population 3. In Pakistan, it 
formed the largest subtype of astrocytic tumours (40.4%), as was reported in a single-center 
study of 761 cases of CNS tumours conducted in the years 2009-2013 4. The current available 
treatment constitutes safe surgical resection, radiation therapy and medications including 
temazolamide (TMZ) and as of latest, avastin, which may marginally improve quality of life 
but not significantly prolong survival 2,5.  
Several environmental and genetic factors have been investigated but none has been 
identified as a risk factor for the larger proportion of GBMs. Cigarette smoking, alcohol use, 
drug use of any kind or dietary intake of N-nitroso compounds and the use of mobile phones 
have all been studied and revealed insubstantial evidence of any association with GBM 6. 
However, there is growing evidence and consensus for the association of certain viruses with 
GBM 7. 
Human cytomegalovirus (HCMV) is a β-herpes virus infamous for developing encephalitis 
in-utero and in immunocompromised adults. This double-stranded enveloped DNA virus is 
complex in its virology with 59 viral proteins and 70 host proteins identified, with mostly 
unknown functions 8. It persists as a latent life-long infection since it can control immune 
responses effectively, and is asymptomatic at primary infection in healthy adults 9. Not 
regarded as an oncogenic virus, HCMV is instead proposed to be an oncomodulator, meaning 
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it infects tumour cells and increases their malignancy without direct transformation 10. 
Moreover, it has also shown oncogenic transformation potential in cancers of the breast 11.  
The first study to report HCMV in GBM was conducted by Cobbs et al. in 2002 12 and ever 
since there have been many studies citing presence and others reporting absence of HCMV in 
glioblastoma 7,13-18.  
Along with HCMV, Human papillomavirus (HPV) is also being investigated for any 
association with high grade gliomas. HPV  has over 200 recognized types and belongs to the 
Papillomaviridae family 19. It is an oncogenic virus notably associated with cervical 
carcinoma as a causative agent and has increasingly become popular in vaginal, penile and 
even oropharyngeal carcinoma 20-22. The type most commonly responsible for oncogenesis is 
the high-risk type HPV16 and HPV18 while low-risk types like HPV6 are more often linked 
with benign lesions 19,23. E6 and E7 are the core genes in HPV, driving the dysregulation of 
cell proliferation and the apoptotic pathways 24-26. These genes have been shown to amplify 
cell proliferation and self-renewal characteristics of neural progenitor cells presumably by 
breaking down p53 and pRb proteins, giving rise to the effects HPV oncogenic proteins may 
have on the CNS 27. So far, only two studies have investigated the presence of HPV in GBM 
and revealed that a high percentage of GBMs are infected by HPV 18 and this in turn leads to 
a worse prognosis 28. 
The subject of HPV and HCMV co-infection has also garnered interest. HPV and HCMV co-
infection has been reported to lead to a two-fold increase in lymph node metastasis in cervical 
tumours 29. Additionally, HCMV infection was also associated with a six-fold increase in 
integrated forms of HPV16 in cervical lesions and contributed to the development of cervical 
cancer 30.  
Apart from viruses, overexpression of certain molecular markers is also thought to contribute 
to GBM development and progression. The expression of Epidermal Growth Factor Receptor 
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(EGFR), Cycloxygenase-2 (COX2), Cyclin D1 and p53 have been found to be elevated in 
GBM and have been correlated with clinical outcome and treatment response. The 
pathogenesis of GBM is not clearly understood despite much research and a viral infection is 
believed to be responsible for at least some GBM cases. The role of Human Cytomegalovirus 
(HCMV) in GBM formation is most convincing among all viruses, but unanimous evidence 
for its use as a therapeutic agent and possible oncogenic factor is missing. Since HPV has 
high incidence in our population and is thought to play a part in various cancers, we aim to 
study its presence in GBM patients as well and any HCMV/HPV co-infection that may be 
present. 
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MATERIALS AND METHODS 
This study was a retrospective series. A total of 112 patients who had been diagnosed with 
and treated for GBM at Aga Khan University Hospital (AKUH) in the years 2015-2016 were 
recruited. The study was given ethical approval by the Ethical Review Committee of AKUH 
(ERC number: 4197-Sur-ERC-17). Written informed consent for participation was taken 
prior to the study and patient information and follow up data was collected using medical 
records and patient follow up visits. Formalin-fixed paraffin-embedded biopsies were used to 
extract genomic DNA by QIAamp DNA Mini Kit (QIAGEN GmbH, Hilden Germany) 
according to the manufacturer’s protocol. 25 μL PCR reaction mixtures for CMV, HPV and 
β-globin were prepared using (GoTaq® Green Master Mix) according to manufacturer’s 
protocol. All primers sequences used are outlined in Table 1. 
CMV detection 
Nested PCR was performed using external and internal oligonucleotide primers specific for 
CMV glycoprotein B gene 31 and PC03/PC04 for β-globin. The PCR thermal profile started 
with initial denaturation for 15 min at 95°C. Then 45 amplification cycles were performed as 
follows: denaturing at 94°C for 30s, annealing for 30s at 56°C, and extension at 72°C for 40s. 
A final extension at 72°C for 10 min completed the PCR amplification. For β-globin, the 
PCR thermal profile was 94°C for 5 min, followed by 40 cycles of 94°C for 30s, 51°C for 
30s, 72°C for 30s, and 5 min final extension at 72°C. 
HPV detection 
Samples were analyzed for HPV by PCR using four sets of primers, i.e., GP5/GP6, general 
primers for HPV; TS16-A/TS16-B and TS18-A/TS-18B as subtype-specific primers for HPV 
subtypes 16 and 18, respectively 32 and PC03/PC04 for β-globin 33. The PCR thermal profile 
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was as follows: 95°C for 5 min, then 40 cycles of 94°C for 30s, 45°C for 30s, 72°C for 30s, 
and final extension of 5 min at 72°C. PCR conditions for HPV 16 and 18 were the same as 
those for general primers (GP), except that the annealing temperatures were 58°C and 60°C, 
respectively. For β-globin, the thermal profile is mentioned above. 
PCR products were separated on agarose gel (2%) premixed with 0.5 µg/ml ethidium 
bromide. The size of the resolved products was determined either with 100bp Plus DNA 
ladder. Agarose gel was run at 120 V for 15 minutes, observed under UV light and 
photographed. 
Samples that resulted positive for HPV were confirmed by sequencing. Amplified PCR 
products of general and type-specific HPV16 and HPV18 were sent to Macrogen South 
Korea, Inc. (http://www.macrogen.com/ko/main/index.php) for gene sequencing. The 
sequenced data was then analysed using BLAST (Basic Local Alignment Search Tool) 
available online at the website of National Centre for Biotechnology Information. 
Molecular markers expression 
Samples that resulted positive for HPV were further analyzed using immunohistochemistry 
(IHC) for the status of EGFR, COX2, Cyclin D1 and p53. All staining was performed using 
primary antibodies from Dako, Denmark, according to manufacturer’s recommendations, 
previously optimized protocols and scoring criteria 34,35. 
Statistical methods 
Analysis was performed using SPSS version 22. Descriptive analysis were performed, for 
continuous variables Mean± S.D or Median (IQR) was reported depending on the normality 
assumption of the variables and assessed for  the 2 groups (i.e. HPV positive  and HPV 
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negative) by independent t test or Wilcoxon rank sum (Mann Whitney test) respectively.  For 
Categorical variables frequency with percentages was reported and was assessed for the 2 
groups by chi-square test of independence if frequency in each cell is ≥5 and if frequency 
was less than 5 in any cell fisher’s exact test was used.  
Follow-up time for each patient was calculated in months.  The overall survival time was 
measured from the date of surgery to the date of death (treatment failure) or, if the patient 
was alive, then until the date of last follow-up. Patients who were alive at the time of last 
contact were considered as censored observation in overall survival analysis.  Kaplan-Meier 
survival curves, log-rank tests and Cox proportional hazards regression analysis were used to 
compare overall survival (death). A second proportional hazard regression model adjusted for 
the other covariates of the study was used to examine the independent effect of treatment.   
Adjusted Hazard Ratio (aHR) with their 95% CI was reported. A p-value of < 0.05 was 
considered as significant. 
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RESULTS 
There were a total of 112 patients in our study comprising of 76 (68%) males and 36 (32%) 
females. Patients ranged from 6 - 81 years of age with the mean age of our study population 
being 47.83 years (SD ± 15.85). The type of brain tumour in all patients was a glioblastoma 
(WHO astrocytoma Grade IV).  
HCMV was positive in a single patient, who was a 61 year old female and tested negative for 
HPV status. For HPV detection, general primers were used which resulted positive in 31 
(28%) patients. Out of these 31 positive specimens, 18 (16%) were detected as HPV16 
positive, 22 (20%) were HPV18 and 2 specimens were not type 16 or 18 and were classified 
as HPV others (Figure 1). Co-infection of HPV16 and HPV18 was seen in 11 out of 31 cases. 
For confirmation of HPV presence, positive PCR products for HPV general and type specific 
16 and 18 were confirmed through sequencing. There was 99% compatibility between our 
PCR and gene sequencing results. A total of 11 patients exhibited co-infection of HPV16 and 
HPV18 both. Any correlations between HPV positivity and patient clinicopathological 
factors were tested using Chi-square or Fishers’ exact test, wherever necessary. There was no 
significant association between any patient factor and HPV status as listed in Table 2.  
The status of molecular markers EGFR, COX2, Cyclin D1 and p53 was tested using IHC on 
the HPV positive specimens (n=31). Each case of HPV positive GBM overexpressed at least 
one of the molecular markers tested, with COX2 being the most frequent (n= 20/31), 
followed by Cyclin D1 (n= 19/31), p53 (n= 15/31) and EGFR (n= 14/31). Co-expression of 
EGFR, Cyclin D1 and COX2 all together was also regularly observed (16%), but none of the 
molecular markers were correlated with one another, as established using the Phi test (p= 
>0.05).  Furthermore, H&E slides of all cases were reviewed by two independent 
histopathologists to identify any differentiating features based on HPV infection. However, 
no remarkable differences in microscopic features were observed. Typical microscopic 
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features of GBM such as presence of necrotic areas, “chicken-wire” network of blood 
vessels, pleomorphic cells with elongated hyperchromatic nuclei, eosinophilic cytoplasm and 
endothelial proliferation were observed. All cases were positive for GFAP and an 
overwhelming majority had increased ki-67 expression, though to varying degrees.  
To study the effect of HPV infection on overall survival of glioblastoma patients, Kaplan-
Meier survival curves, log-rank tests and Cox proportional hazards regression analysis were 
performed. Complete survival data was available for 60 out of 112 patients. The overall mean 
survival time for the study participants was 10.3 months, while the survival time of the 
CMV+ patient was 16 months. Figure 2 shows the Kaplan-Meier curves for HPV+ and HPV- 
patients. It was observed that HPV positive patients had longer survival times (13 months) in 
comparison to HPV negatives ones (9 months). However, this did not translate to statistical 
significance (Table 3). Moreover, age was significantly correlated with overall survival as 
with every one year increase in age the hazard of death was increased by 3%.  
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DISCUSSION 
This study is the first to explore the role of infectious agents HCMV and HPV in 
glioblastoma patients of Pakistan. We found a high prevalence of HPV in our GBM 
population and a single case of HCMV infection. A novel finding of our study was the co-
infection of HPV16 and 18 found in 11 out of 31 cases. Upon correlation with overall 
survival, it was found that HPV infection did not have any statistically valid effect on the 
prognosis of GBM patients, although HPV positive patients did have longer survival times 
than their negative counterparts. We further investigated any histological differences 
occurring due to HPV infection, but found no discerning features in the HPV positive cases. 
The expression of commonly used biomarkers EGFR, COX2, Cyclin D1 and p53 was 
assessed in HPV positive cases and at least one marker was overexpressed in all cases, with 
COX2 being the most common. The trio of EGFR, COX2 and Cyclin D1 was overexpressed 
together in 16% cases, although no correlations among any of the markers could be 
established statistically. 
There are certain features typical to the majority of GBM cases. These include the male sex, 
age close to 45 years, white race, prior exposure to ionizing radiation and certain underlying 
genetic disorders such as tuberous sclerosis, neurofibromatosis type 1 & 2, Turcot syndrome 
and Li-Fraumeni syndrome2. These findings are consistent with our cohort, as there were 
76% males as compared to 36% females and the mean age was 47 years. Similar figures were 
reported by Ahsan et al36. who performed a single-centre study showing that the mean age 
was 47 years in Pakistan as compared to the 64 years on presentation in the US1.  
Viral infections have been linked to the development of a spectrum of clinical disorders 
including cancer. In the Pakistani population, the seroprevalence of HCMV was found to be 
very high at 93.2% for IgG and 4.3% for IgM respectively37. Other local studies have found 
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HCMV infection to be responsible for congenital defects among neonates and 6% of 
Pakistani women of childbearing age are at risk of primary infection38,39. 
Over a decade has passed since the discovery of HCMV in a few GBM samples by Cobbs et 
al.12. In our cohort of 112 patients we found only one case of HCMV infection. There was no 
correlation of HCMV positivity with any of the clinicopatholgical factors tested. Another 
study by Lau et al. also reported complete absence of HCMV in various carcinomas and 
sarcomas using immunohistochemistry, in situ hybridization and PCR13. Since the results of 
Cobbs et al. have not been reproduced satisfactorily, the association of HCMV with GBM is 
still not established. It is hypothesized that HCMV may give rise to gliomagenesis, enhance 
tumourigenesis or reactivate itself in tumour formation and the latest consensus is that the 
role of HCMV cannot be ignored7. The results of HCMV may not be sufficient to show a 
direct association with GBM, however, the possibility of a link cannot be completely ruled 
out for the population of Pakistan. As suggested by previous researches conducted in Japan 
where HCMV was not detected, geographical variation may be a possible explanation for this 
outcome18. Various studies have concurred that the presence and role of HCMV in GBM 
cannot be excluded at the very least7. 
The Pakistani population also suffers from high HPV incidence. A study by Bruni at al. in 
2012 found that 88% of all cases of cervical carcinoma were due to HPV infection, while the 
incidence of HPV-related other cancers in males was 2.4 per 100,000 40. Moreover, HPV16 
was found to be significantly associated with cervical cancer in Pakistani women and oral 
squamous cell carcinoma in Pakistani men41,42.  
HPV, in its limited research with brain tumor tissue, has emerged as a virus consistent in its 
outcomes with all three studies, including ours. Vidone et al. established the existence of 
HPV in GBM specimens from the eastern European population where 23% of samples tested 
positive, in which 25% showed HPV16 dominance associated with poor prognosis28.  The 
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first study done on the Asian population to check for the presence of eight known oncogenic 
viruses showed 21% of samples to be HPV positive while no other viruses were detected18. 
Our results show presence of HPV in 28% of GBM patients, out of which the majority were 
infected with HPV18. We also found positivity of HPV16 and 18 both in 11 cases which was 
a finding unique to our cohort. Existing literature on Pakistani patients shows us that HPV16 
was more prevalent than type18 for oral and cervical cancer both41,42. Moreover, in our 
current GBM study as well as in the previously published oral cancer study42, the majority of 
HPV positive patients were male. This begs further investigation into how males are more 
susceptible or more exposed to HPV infections in oral as well as brain cancers. 
As mentioned earlier, the E6 and E7 core genes of HPV can cause the dysregulation of 
various processes responsible for oncogenic transformation in the CNS27. Moreover, heparin 
sulfate proteoglycans (HSPG) have been found to be the primary binding sites for HPV 
virions which are an element of the cellular components of the brain, as also suggested by 
Vidone et al. 28,43,44.  
The overexpression of molecular markers observed in HPV positive cases corresponds with 
present literature. EGFR is found overexpressed in 60% of primary glioblastomas45 , COX2 
in 75% of glioblastoma46, Cyclin D1 in 31% of low grade and 62% of high grade gliomas47 
and p53 in 42% of low-grade and 64% of high grade gliomas48 . However, we did not find 
any literature regarding the association of HPV and EGFR, COX2, Cyclin D1 and p53 in 
GBM. Nevertheless, we did find overexpression of at least one biomarker in all HPV positive 
cases and COX2 overexpression was the most common at 65%. 
Our findings make a strong case for further investigation into the role of viruses in 
gliomagenesis and the molecular basis for this neoplasia. If HPV is a causative factor for 
GBM then preventive measures may be applied as is the case with HPV-induced cervical 
cancer patients which may prolong patient survival. 
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CONCLUSIONS 
 
Our findings make a strong case for further investigation into the role of viruses in 
gliomagenesis and the molecular basis for this neoplasia. Since CMV was very scarce in our 
study we propose other factors may be influencing the development of gliomas in the 
Pakistani population. If HPV is a causative factor for GBM, which needs further 
investigation, then preventive measures may be applied as is the case with HPV-induced 
cervical cancer patients which may prolong patient survival. 
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FIGURE CAPTIONS 
 
 
Figure 1: Kaplan Meier survival curves in 60 GBM patients selected according to (A) CMV 
status, (B) HPV status, (C) HPV16 status and (D) HPV18 status  
 
Figure 2 (A): PCR amplification of HPV general, HPV type 16 and HPV type 18 in GBM 
samples. Products were electrophoresed on 2% agarose gel and stained with ethidium 
bromide. From left to right: sample 117 is HPV-, 118 and 119 are HPV+ with positive 
control marked, DNA ladder of 100bp, positive control of HPV18, sample 4 HPV18+, 
positive control of HPV16 and sample 4 HPV16+. It is to be noted that sample 4 has co-
infection of HPV16 and HPV18 
Figure 2 (B): PCR amplification of HCMV in GBM samples. Products were electrophoresed 
on 2% agarose gel and stained with ethidium bromide. From left to right: DNA ladder of 
100bp, negative control, positive control of CMV, samples 3, 5, 6 and 7 are CMV- and 
sample 4 is CMV+. 
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Table 1 Primers used for PCR 
 Primer Sequence Target 
gene 
Amplimer 
length 
HPV 
General 
GP5 TTTGTTACTGTGGTAGATACTAC L1 155 bp 
GP6 GAAAAATAAACTGTAAATCATATTC 
HPV 
type16  
TS16-A GGTCGGTGGACCGGTCGATG L1 96 bp 
TS16-B GCAATGTAGGTGTATCTCCA 
HPV 
type 18 
TS18-A CCTTGGACGTAAATTTTTGG L1 115 bp 
TS18-B CACGCACACGCTTGGCAGGT 
β-globin  PC03 ACACAACTGTGTTCACTAGC β-Globin 110 bp 
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PC04 CAACTTCATCCACGTTCACC 
CMV CMVXF TCCAACACCCACAGTACCCGT glycoprotein 
B 
267 bp 
CMVXR CGGAAACGATGGTGTAGTTCG 
CMVIF TGACGGTCAAGGATCAGTGGC 146 bp 
CMVIF GTAAACCACATCACCCGTGGA 
Table 2 Correlation of HPV status with patient characteristics (n=112) 
Factors 
Total 
HPV Status 
P value 
Positive 
(n=31) 
Negative 
(n=81) 
N % 
N % N %  
Gender Male 76 68 23 74 53 65 0.374 
Female 36 32 8 26 28 35 
Site of 
Lesion 
Brain 27 24 4 13 23 28 0.195 
Frontal 13 12 2 7 11 14 
Parietal 16 14 7 23 9 11 
Temporal 28 25 8 26 20 25 
Occipital 2 2 1 3 1 1 
Fronto-
Parietal 
8 7 3 10 5 6 
Fronto-
temporal 
3 3 0 0 3 4 
Temporo-
parietal 
7 6 2 7 5 6 
Parieto-
Occipital 
4 4 3 4 3 4 
Others 4 4 3 10 1 1 
Living 
Status 
Alive 17 15 6 19 11 14 0.233 
Dead 43 39 8 26 35 43 
LFUP 52 46 17 55 35 43 
HCMV Positive 1 1 0 0 1 1 >0.99 
Negative 111 99 31 100 80 99 
p-value considered significant at <0.05  
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Table 3 Correlation of clinicopathologic factors with HPV status of GBM patients (n=60) 
UNIVARIATE ANALYSIS 
Factor Group 
Overall survival 
N Months P-value 
Hazard 
ratios 
95% Confidence 
interval  
Lower Upper 
Age - 112 - 0.008* 1.029 1.008 1.052 
Gender Male 76 10 .970 0.987 0.498 1.957 
Female 36 10 1   
Site of 
Lesion 
Brain 27 10 0.757 0.885 0.396 1.979 
Frontal 13 9 0.837 0.315 2.220 
Parietal 16 4 1.838 0.587 5.753 
Temporal 28 9 1   
Occipital 2 14 0.395 0.051 3.031 
Fronto-
Parietal 
8 7 1.050 0.236 4.681 
Fronto-
temporal 
3 5 1.753 0.225 13.692 
Temporo-
parietal 
7 15 0.277 0.036 2.125 
Parieto-
Occipital 
4 12 0.450 0.058 3.463 
HPV Positive 31 13 0.399 0.715 0.328 1.560 
Negative 81 9 1   
HPV16 Positive 18 13 0.537 0.744 0.291 1.901 
Negative 94 10 1   
HPV18 Positive 22 13 0.498 0.753 0.332 1.711 
Negative 90 10 1   
MULTIVARIATE ANALYSIS 
Factor Group 
Overall survival    
N P - 
value 
HR 95% Confidence 
interval 
     Lower Upper 
Age - 112 0.013* 1.029 1.006 1.052 
HPV Positive 31 0.825 0.913 0.407 2.047 
 Negative 81 
*p-value considered significant at <0.05 
Months for overall survival were calculated through Kalpan Meier Log Rank test 
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